EyePoint's DURAVYU misses Phase 2 NPDR primary endpoint; shows reduced progression at 9 months

EyePoint, Inc.

Primary endpoint not met: 5% (3mg), 0% (2mg) vs 5% control achieved ≥2-step DRSS improvement at 9 months.
86% (3mg) and 80% (2mg) patients stable/improved vs 70% control; 0% (3mg) worsened ≥2-step vs 10% control.
No drug-related serious adverse events reported; favorable safety profile maintained.
Company on track for Phase 3 wet AMD trial (LUGANO) in H2 2024 and DME trial (VERONA) data in Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.